EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis


ABSTRACT

Objective To develop evidence-based recommendations for the diagnosis of knee osteoarthritis (OA).

Methods The multidisciplinary guideline development group, representing 12 European countries, generated 10 key propositions regarding diagnosis using a Delphi consensus approach. For each recommendation, research evidence was searched systematically. Whenever possible, the sensitivity, specificity and likelihood ratio were calculated for individual diagnostic indicators and a diagnostic ladder was developed using Bayes’ method. Secondary analyses were undertaken to test directly the recommendations using multiple predictive models in two populations from the UK and the Netherlands. Strength of recommendation was assessed by the EULAR visual analogue scale.

Results Recommendations covered the definition of knee OA and its risk factors, subsets, typical symptoms and signs, the use of imaging and laboratory tests and differential diagnosis. Three symptoms (persistent knee pain, limited morning stiffness and reduced function) and three signs (crepitus, restricted movement and bony enlargement) appeared to be the most useful. Assuming a 12.5% background prevalence of knee OA in adults aged ≥45 years, the estimated probability of having radiographic knee OA increased with increasing number of positive features, to 99% when all six symptoms and signs were present. The performance of the recommendations in the study populations varied according to the definition of knee OA, background risk and number of tests applied.

Conclusion 10 key recommendations for diagnosis of knee OA were developed using both research evidence and expert consensus. Although there is no agreed reference standard, thorough clinical assessment alone can provide a confident rule-in diagnosis.

INTRODUCTION

Osteoarthritis (OA) is the third most common diagnosis made by general practitioners in older patients and OA is the most common arthropathy to affect the knee. About 25% of adults aged >55 years experience significant knee pain; half of these have radiographic changes of OA and a quarter have significant disability. Risk factors for knee OA include ageing, female gender, being overweight, prior knee injury and a positive family history. However, knee OA is not a discrete entity, showing variability with respect to compartmental involvement, accompanying inflammation and calcium crystal deposition, concurrence of OA at other joint sites and outcome.

Classification criteria developed by the American College of Rheumatology (ACR) in 1986 are often used to standardise case definitions for research purposes. Currently there is no guideline primarily for the purpose of clinical diagnosis of knee OA. Radiography is often used as the ‘gold standard’, but it is not the only marker for OA. Definition of knee OA may change according to different levels of care and clinical requirements. Therefore the EULAR OA Task Force undertook the following project to develop evidence-based recommendations for diagnosis of knee OA using a systematic review of research evidence and expert consensus. Performance of the recommendations was tested in two European populations. The target audience for these recommendations is any health professional who is involved with the diagnosis of knee OA.

METHODS

A multidisciplinary guideline development group, comprising 17 OA experts from 12 European countries, was commissioned by the EULAR Standing Committee for Clinical Affairs (ESCCA). After a single face-to-face meeting, each participant independently submitted up to 10 propositions related to key aspects in the diagnosis of knee OA. Consensus was reached using the Delphi technique. As with previous EULAR projects to develop recommendations for diagnosis, a systematic search of the literature published between January 1950 and January 2008 was undertaken; the search for knee OA was combined with searches for diagnostic test and study design (online supplementary data, Appendices 1–7). Further search for specific diagnostic test/feature was undertaken after consensus to ratify the evidence.

Outcome measures

As there is no agreed single reference standard for the diagnosis of knee OA, a pragmatic decision was made to take account of studies that included either clinical, radiographic, MRI or arthroscopic reference standards. The ability of individual tests to discriminate between patients with and without knee OA was then summarised by sensitivity, specificity and likelihood ratios (LRs) (LR=sensitivity/(1−specificity)). LRs >10 or <0.1 are considered strong evidence to respectively rule in or rule out a diagnosis in most circumstances. The probability of having knee OA given a positive test result was estimated using Bayes’ theorem. Test reliability was summarised...
Recommendations

using χ statistics (dichotomous data) and intraclass correlation coefficients (continuous data). Relative risk (RR) and odds ratio (OR) were calculated for risk factors and comorbidities associated with knee OA. For economic evaluations, the incremental cost-effectiveness ratio (ICER) was presented. Best available evidence was used according to the EULAR evidence hierarchy for diagnosis (Ia, meta-analysis of cohort studies; Ib, meta-analysis of case–control or cross-sectional studies; IIa, cohort studies; IIb, case–control or cross-sectional studies; III, non-comparative descriptive studies; IV, expert opinion). Statistical pooling was undertaken as appropriate within the same study design if there was no systematic review, and a random effects model was used when the results were heterogeneous. Strength of recommendation (SOR) was graded using the EULAR 0–100 mm visual analogue scale (VAS). The performance of the recommended tests was examined in two populations, where multiple logistic regression was used to estimate the likelihood of knee OA given a composite of the diagnostic tests. All measures were reported with 95% CI unless otherwise specified.

Future research agenda

After the propositions for diagnosis had been searched, reviewed and discussed, each participant submitted independently 10 propositions for future research. Consensus was again obtained using the Delphi technique.

RESULTS

Systematic literature search

The literature search yielded 1738 hits. After deleting duplicates, 1604 studies remained, of which 313 met the inclusion criteria (figure 1). Clinical features (56%) and radiographs were the most often used reference standards (35%). The majority of studies were cross-sectional (55%), followed by case–control (29%), cohort (13%) and systematic review (3%). No randomised controlled trials or economic evaluations were identified from the search.

EULAR recommendations

Of 166 propositions suggested initially, 10 were agreed after four anonymous Delphi rounds. Recommendations covered the definition of knee OA and its risk factors, subsets, typical symptoms and signs, the use of imaging and laboratory tests and differential diagnosis (table 1). Evidence for validity (sensitivity, specificity, etc) and reliability of each diagnostic test/feature are summarised in table 2. Three symptoms (persistent knee pain, limited morning stiffness and reduced function) and three signs (crepitus, restricted movement and bony enlargement) appeared to be the most useful. Assuming a 12.5% background prevalence of knee OA in adults aged ≥45 years, the estimated probability of having radiographic knee OA increased with increasing number of positive features, to 99% when all six symptoms and signs were present (figure 2). Strength of recommendation was generated based on research evidence and clinical expertise with 95% CI (table 1). Details of each recommendation and supporting evidence are available online (supplementary file) in EULAR recommendations for the diagnosis of knee OA and supporting evidence.

Performance of recommendations

The two populations selected had investigated plain radiographs and clinical features, permitting performance testing for some of the recommendations.

In the UK

We used cross-sectional data from the Knee Clinical Assessment Study (CAS(K)) conducted in North Staffordshire, UK. After excluding 16 people with a pre-existing diagnosis of inflammatory arthritis, 745 adults with knee pain aged ≥50 years (mean age 65 years, SD 8.6, range 50–93; 56% female; mean body mass index (BMI) 29.6 kg/m², 41% obese) were available for analysis.

Of 745, 570 (76%) and 292 (39%) subjects had radiographic OA according to two definitions based on standing posteroanterior, supine lateral and supine skyline views: osteophytosis (broadly equivalent to Kellgren and Lawrence score (KL) ≥1)
Table 1  Propositions and strength of recommendation (SOR)—order according to topic (definition, subsets, symptoms, physical findings, images, laboratory tests, risk factors and differential diagnosis)

<table>
<thead>
<tr>
<th>No</th>
<th>Proposition</th>
<th>LoE</th>
<th>SOR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Knee OA is characterised clinically by usage-related pain and/or functional limitation. It is a common complex joint disorder showing focal cartilage loss, new bone formation and involvement of all joint tissues. Structural tissue changes are mirrored in classical radiographic features</td>
<td>Ib</td>
<td>88 (83 to 92)</td>
</tr>
<tr>
<td>2</td>
<td>Risk factors that are strongly associated with the incidence of knee OA can help to identify patients in whom knee OA is the most likely diagnosis. These include increasing age over 50 years, female gender, higher body mass index, previous knee injury or malalignment, joint laxity, occupational or recreational usage, family history and the presence of Heberden’s nodes</td>
<td>Ib–IIb</td>
<td>89 (83 to 95)</td>
</tr>
<tr>
<td>3</td>
<td>Subsets with different risk factors and outcomes can be defined according to var...</td>
<td>Ib–IIb</td>
<td>75 (63 to 87)</td>
</tr>
<tr>
<td>4</td>
<td>Typical symptoms of knee OA are usage-related pain, often worse towards the end of the day, relieved by rest; the feeling of ‘giving way’; only mild morning or inactivity stiffness and impaired function. More persistent rest and night pain may occur in advanced OA. OA symptoms are often episodic or variable in severity and slow to change</td>
<td>Ib–IIb</td>
<td>76 (64 to 87)</td>
</tr>
<tr>
<td>5</td>
<td>In adults aged &gt;40 years with usage-related knee pain, only short-lived morning stiffness, functional limitation and one or more typical examination findings (crepitus, restricted movement, bony enlargement), a confident diagnosis of knee OA can be made without a radiographic examination. This applies even if radiographs appear normal</td>
<td>Ib</td>
<td>80 (67 to 92)</td>
</tr>
<tr>
<td>6</td>
<td>All patients with knee pain should be examined. Findings indicative of knee OA include crepitus; painful and/or restricted movement; bony enlargement and absent or modest effusion. Additional features that may be present include deformity (fixed flexion and/or varus)—less commonly valgus; instability; periaricular or joint-line tenderness and pain on patellofemoral compression</td>
<td>Ib–III</td>
<td>90 (85 to 95)</td>
</tr>
<tr>
<td>7</td>
<td>Red flags (eg, severe local inflammation, erythema, progressive pain unrelated to usage) suggest sepsis, crystals or serious bone involvement. Other joint involvement may suggest a wide range of alternative diagnoses. Other important considerations are referred pain, ligamentous and meniscal lesions and localised bursitis</td>
<td>IV</td>
<td>87 (80 to 94)</td>
</tr>
<tr>
<td>8</td>
<td>Plain radiography (both knees, weightbearing, semiflexed PA (MTP) view, plus a lateral and skyline view) is the current ‘gold standard’ for morphological assessment of knee OA. Classical features are focal joint space narrowing, osteophyte, subchondral bone sclerosis and subchondral ‘cysts’. Further imaging modalities (MRI, sonography, scintigraphy) are seldom indicated for diagnosis of OA</td>
<td>Ib–IIb</td>
<td>83 (71 to 95)</td>
</tr>
<tr>
<td>9</td>
<td>Laboratory tests on blood, urine or synovial fluid are not required for the diagnosis of knee OA, but may be used to confirm or exclude coexistent inflammatory disease (eg, pyrophosphate crystal deposition, gout, rheumatoid arthritis) in patients with suggestive symptoms or signs</td>
<td>Ib</td>
<td>86 (78 to 94)</td>
</tr>
<tr>
<td>10</td>
<td>If a palpable effusion is present, synovial fluid should be aspirated and analysed to exclude inflammatory disease and to identify urate and calcium pyrophosphate crystals. OA synovial fluid is typically non-inflammatory with &lt;2000 leucocytes/mm3; if specifically sought, basic calcium phosphate crystals are often present</td>
<td>Ib</td>
<td>73 (56 to 89)</td>
</tr>
</tbody>
</table>

LoE, level of evidence (Ia, meta-analysis of cohort studies; Ib, meta-analysis of case–control or cross-sectional studies; IIa, cohort study; IIb, case–control or cross-sectional studies; III, non-comparative descriptive studies; IV, expert opinion); SOR, strength of recommendation on visual analogue scale (0–100 mm; 0—not recommended at all, 100=fully recommended).

Table 2  Validity and reliability of diagnostic tests in the diagnosis of knee osteoarthritis—pooled results

<table>
<thead>
<tr>
<th>Test</th>
<th>No of studies (designs)</th>
<th>No of subjects</th>
<th>Mean age (range)</th>
<th>F%</th>
<th>Reference standards</th>
<th>Sensitivity (95% CI)</th>
<th>Specificity (95% CI)</th>
<th>LR (95% CI)</th>
<th>ICC/kappa (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age ≥50</td>
<td>1 (cs)</td>
<td>2865</td>
<td>–</td>
<td>54</td>
<td>Radiographic</td>
<td>0.90 (0.80 to 0.95)</td>
<td>0.23 (0.14 to 0.32)</td>
<td>1.20 (0.69 to 2.52)</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>2 (cc, 1 cs)</td>
<td>3102</td>
<td>–</td>
<td>55</td>
<td>Clinical or radiographic</td>
<td>0.76 (0.69 to 0.83)</td>
<td>0.31 (0.22 to 0.40)</td>
<td>1.10 (0.94 to 1.29)</td>
<td>–</td>
</tr>
<tr>
<td>Knee pain</td>
<td>7 (1 cc, 6 cs)</td>
<td>5401</td>
<td>62 (40–92)</td>
<td>62</td>
<td>Clinical, radiographic or MRI</td>
<td>0.59 (0.40 to 0.77)</td>
<td>0.62 (0.45 to 0.79)</td>
<td>1.57 (1.26 to 1.96)</td>
<td>–</td>
</tr>
<tr>
<td>Persistent*</td>
<td>3 (3 cs)</td>
<td>1505</td>
<td>(40–79)</td>
<td>100</td>
<td>Clinical, radiographic or MRI</td>
<td>0.53 (0.47 to 0.58)</td>
<td>0.71 (0.62 to 0.79)</td>
<td>1.67 (1.44 to 1.94)</td>
<td>–</td>
</tr>
<tr>
<td>Usage-related</td>
<td>4 (1 cc, 3 cs)</td>
<td>3896</td>
<td>72 (50–92)</td>
<td>54</td>
<td>Radiographic</td>
<td>0.95 (0.91 to 0.99)</td>
<td>0.19 (0.11 to 0.26)</td>
<td>1.16 (1.15 to 1.29)</td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>5 (3 cc, 2 cs)</td>
<td>1945</td>
<td>64 (50–90)</td>
<td>54</td>
<td>Clinical or radiographic</td>
<td>0.56 (0.50 to 0.61)</td>
<td>0.63 (0.40 to 0.87)</td>
<td>1.50 (1.23 to 1.84)</td>
<td>–</td>
</tr>
<tr>
<td>Morning stiffness</td>
<td>3 (1 cc, 2 cs)</td>
<td>3151</td>
<td>67 (50–92)</td>
<td>79</td>
<td>Clinical or radiographic</td>
<td>0.88 (0.82 to 0.93)</td>
<td>0.52 (0.43 to 0.62)</td>
<td>1.84 (1.49 to 2.27)</td>
<td>0.99 (0.74 to 1.30)</td>
</tr>
<tr>
<td>Crepitus</td>
<td>4 (2 cc, 2 cs)</td>
<td>942</td>
<td>65 (50–92)</td>
<td>72</td>
<td>Clinical or radiographic</td>
<td>0.89 (0.85 to 0.93)</td>
<td>0.60 (0.54 to 0.67)</td>
<td>2.23 (1.90 to 2.63)</td>
<td>0.76 (0.60 to 0.96)</td>
</tr>
<tr>
<td>Bony enlargement</td>
<td>3 (1 cc, 2 cs)</td>
<td>3108</td>
<td>59 (44–74)</td>
<td>55</td>
<td>Clinical or radiographic</td>
<td>0.95 (0.91 to 0.99)</td>
<td>1.11 (0.94 to 2.28)</td>
<td>0.91 (0.61 to 1.31)</td>
<td>–</td>
</tr>
<tr>
<td>Restricted movement</td>
<td>6 (3cc,2cs,1a)</td>
<td>3661</td>
<td>62 (50–90)</td>
<td>54</td>
<td>Clinical or radiographic</td>
<td>0.55 (0.46 to 0.64)</td>
<td>0.96 (0.91 to 0.99)</td>
<td>11.81 (4.94 to 28.22)</td>
<td>–</td>
</tr>
<tr>
<td>Palpable effusion</td>
<td>2 (1 cc, 1 cs)</td>
<td>3752</td>
<td>55 (50–90)</td>
<td>55</td>
<td>Clinical or radiographic</td>
<td>0.43 (0.34 to 0.52)</td>
<td>0.41 (0.32 to 0.50)</td>
<td>0.73 (0.56 to 0.95)</td>
<td>–</td>
</tr>
<tr>
<td>Instability</td>
<td>2 (1 cc, 1 cs)</td>
<td>243</td>
<td>58 (44–82)</td>
<td>72</td>
<td>Clinical or radiographic</td>
<td>0.26 (0.19 to 0.34)</td>
<td>0.26 (0.20 to 0.32)</td>
<td>1.25 (0.89 to 1.77)</td>
<td>–</td>
</tr>
<tr>
<td>JSN</td>
<td>8 (4 cc, 4 cs)</td>
<td>2815</td>
<td>55 (25–80)</td>
<td>78</td>
<td>Clinical, radiographic or arthroscopic</td>
<td>0.44 (0.27 to 0.62)</td>
<td>0.79 (0.68 to 0.92)</td>
<td>2.19 (1.58 to 3.03)</td>
<td>0.66 (0.51 to 0.81)</td>
</tr>
<tr>
<td>OST</td>
<td>8 (5 cc, 6 cs)</td>
<td>3250</td>
<td>57 (25–80)</td>
<td>74</td>
<td>Clinical, radiographic or arthroscopic</td>
<td>0.51 (0.32 to 0.69)</td>
<td>0.83 (0.76 to 0.89)</td>
<td>3.29 (2.41 to 4.48)</td>
<td>0.71 (0.61 to 0.82)</td>
</tr>
</tbody>
</table>

Continued
The probability of radiographic knee OA increased with an increasing number of positive tests (figure 3). The likelihood of having radiographic knee OA (KL ≥1) was 88% for a person aged >60 years, who is overweight and has crepitus, restricted movement and bony enlargement. The likelihood was smaller when the diagnostic criterion was higher (eg, KL ≥3) (figure 3).

In the Netherlands

The Rotterdam study is a population-based, longitudinal cohort study for incidence and risk factors for chronic disabling conditions. Of 10,275 residents in one district of Rotterdam (Ommoord), 7,983 agreed to participate (mean age 70.6, SD 9.8, range 55–106; 61.1% female, mean BMI 26.3, SD 3.7), 3,456 with baseline knee anteroposterior (AP) x-rays formed the study population for this analysis.

Of 3,456 subjects, 1,624 (47%) and 129 (3.7%) were classified as having knee OA according to the cut-off points KL ≥1 and KL ≥3.

Diagnostic variables examined included age, gender, BMI, knee pain in the past 5 years, morning stiffness, functional impairment, family history of OA, radiographic varus malalignment, hand OA (KL ≥2), hip OA (KL ≥2) and serum C-reactive protein (CRP) <5 mg/l. Of these, gender, morning stiffness, family history, hip OA and CRP were not significant so were excluded from the logistic regression models. Only four clinical features (age, BMI, knee pain and functional limitation) were available to test the performance of the clinical diagnosis. The probability

<table>
<thead>
<tr>
<th>Test</th>
<th>No of studies (designs)</th>
<th>No of subjects</th>
<th>Mean age (range)</th>
<th>F%</th>
<th>Reference standards</th>
<th>Sensitivity (95% CI)</th>
<th>Specificity (95% CI)</th>
<th>LR (95% CI)</th>
<th>ICC/kappa (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sclerosis</td>
<td>5 (3 cc, 2 cs)</td>
<td>788</td>
<td>55 (25–77)</td>
<td>60</td>
<td>Clinical or arthroscopic</td>
<td>0.33 (0.03 to 0.63)</td>
<td>0.89 (0.76 to 1.02)</td>
<td>2.56 (1.92 to 3.42)</td>
<td></td>
</tr>
<tr>
<td>Cysts</td>
<td>2 (cc)</td>
<td>387</td>
<td>53 (35–77)</td>
<td>63</td>
<td>Clinical or arthroscopic</td>
<td>0.24 (−0.04 to 0.51)</td>
<td>0.93 (0.82 to 1.05)</td>
<td>2.98 (1.76 to 5.03)</td>
<td></td>
</tr>
<tr>
<td>SF CPPD</td>
<td>3 (1 cc, 2 cs)</td>
<td>3894</td>
<td>67 (34–98)</td>
<td>51</td>
<td>Clinical or radiographic</td>
<td>0.56 (0.48 to 0.64)</td>
<td>0.70 (0.64 to 0.78)</td>
<td>1.87 (1.46 to 2.40)</td>
<td></td>
</tr>
<tr>
<td>RF (+)</td>
<td>1 (cc)</td>
<td>237</td>
<td>95</td>
<td>73</td>
<td>Clinical</td>
<td>0.05 (0.003 to 0.11)</td>
<td>0.51 (0.40 to 0.63)</td>
<td>0.11 (0.04 to 0.30)</td>
<td></td>
</tr>
</tbody>
</table>

*Most days for at least a month.

cc, case control; CPPD, calcium pyrophosphate dihydrate; cs, cross sectional; ICC, intraclass correlation coefficient; JSN, joint space narrowing; KL, Kellgren and Lawrence; LR, likelihood ratio; DST, osteophyte; RF, rheumatoid factor; SF, synovial fluid; sr, systematic review.

The probability of radiographic knee OA increased with an increasing number of positive tests (figure 3). The likelihood of having radiographic knee OA (KL ≥1) was 88% for a person aged >60 years, who is overweight and has crepitus, restricted movement and bony enlargement. The likelihood was smaller when the diagnostic criterion was higher (eg, KL ≥3) (figure 3).

In the Netherlands

The Rotterdam study is a population-based, longitudinal cohort study for incidence and risk factors for chronic disabling conditions. Of 10,275 residents in one district of Rotterdam (Ommoord), 7,983 agreed to participate (mean age 70.6, SD 9.8, range 55–106; 61.1% female, mean BMI 26.3, SD 3.7), 3,456 with baseline knee anteroposterior (AP) x-rays formed the study population for this analysis.

Of 3,456 subjects, 1,624 (47%) and 129 (3.7%) were classified as having knee OA according to the cut-off points KL ≥1 and KL ≥3.

Diagnostic variables examined included age, gender, BMI, knee pain in the past 5 years, morning stiffness, functional impairment, family history of OA, radiographic varus malalignment, hand OA (KL ≥2), hip OA (KL ≥2) and serum C-reactive protein (CRP) <5 mg/l. Of these, gender, morning stiffness, family history, hip OA and CRP were not significant so were excluded from the logistic regression models. Only four clinical features (age, BMI, knee pain and functional limitation) were available to test the performance of the clinical diagnosis. The probability
of having any radiographic knee OA (KL ≥1) increased gradually with an increasing number of positive tests. It reached 52% when all these clinical features were positive—that is, aged >60 years of age, being overweight and having knee pain and impaired function.

**Future research agenda**

One hundred and thirteen initial propositions were submitted by the Task Force members. After three anonymous Delphi rounds, nine of these obtained over 50% votes and went forward as the proposed future research agenda:

1. Development of internationally agreed criteria sets for diagnosis of knee OA for clinical practice, clinical trials and epidemiological studies.
3. Delineation of the attributable risk factor profile, for both development and progression, for each suggested subset of knee OA.
4. Development of diagnostic criteria for early symptomatic knee OA (eg, by prospective investigation of people with knee pain who fulfill criteria of knee OA several years later).
5. Investigation of whether individual pain patterns (usage-related, episodic, night pain) have different utility as diagnostic markers of knee OA.
6. Determination of clinical, diagnostic and prognostic relevance of MRI changes in knee OA.
7. Determination of the utility of ultrasonography in the diagnosis and prognosis of knee OA.
8. Assessment of the possible role of biomarkers (including genetic markers) in the early diagnosis, phenotypic characterisation and prediction of outcome of knee OA.

**DISCUSSION**

Knee OA can variably involve cartilage, bone, synovium and surrounding tissues of the three biomechanically discrete compartments and may associate with OA at other joints owing to shared genetic and constitutional risk exposures. Thus the clinical phenotype is very variable, requiring consideration of several characteristics for accurate diagnosis. Although the ACR criteria are a useful tool for classification of knee OA, they were developed using hospital-referred patients and a control group that comprised patients with other arthritis (over 50% had rheumatoid arthritis), thus making them most useful for differentiation of knee OA from inflammatory arthritis rather than for diagnosis of knee OA itself in a routine clinical setting. The focus of these current recommendations, however, was on the risk factors, symptoms, signs and tests that might contribute to a clinical diagnosis. Although there is no ‘gold standard’ for diagnosis of knee OA, an important conclusion was that in adults aged ≥45 years, an adequate history and examination alone may lead to a confident clinical diagnosis of knee OA. This is in contrast with the situation in some care settings, in which practitioners devote insufficient time to patient inquiry and physical examination and instead place undue emphasis on tests, especially radiographs.

The recommendations were developed systematically and combine both expert opinion (Delphi exercise) and research evidence (systematic review and meta-analysis). Evidence was derived from both community- and hospital-based studies to improve generalisability. The recommendations have been examined initially in datasets derived from two general populations in Europe.

According to the recommendations and the supporting evidence the diagnosis of knee OA can be made based on the background risk (the population prevalence of knee OA); the patient’s risk factors for OA (eg, age, gender, BMI, occupation); their symptoms (persistent knee pain, brief morning stiffness and functional limitation) and an adequate physical examination (crepitus, restricted movement and bony enlargement). Plain radiographs are the main test to consider, but are an adjunct, rather than a central feature, for the purposes of diagnosis (figure 4). The more positive results a patient presents, the more likely the diagnosis of OA. Knowledge of the background risk (ie, the local source population prevalence of knee OA) is crucial for estimating the likelihood of knee OA. The higher the risk in the source population, the more possible it is to diagnose knee OA based on clinical features.

There are limitations to these recommendations. First, the evidence to support these recommendations was derived largely from literature based on different studies. The LRs (table 2) are unadjusted and the subsequent probabilities are for reference only. The application of these recommendations should be based on the individual patient characteristics and the knee OA risk in the source population. Second, the LRs pooled from the literature may be affected by many factors, such as the number of studies involved, the populations selected (hospital or community), the ‘gold standard’ used and the cut-off values selected. For example, the LR for bony enlargement (11.81, 95% CI 4.94 to 28.22) was mainly based on a hospital-based case–control study where the ‘gold standard’ was clinical diagnosis of knee OA and the controls predominantly were patients with rheumatoid arthritis. The validity and reliability of this LR is questionable, compared with those LRs derived from multiple studies including both hospital and community data, such as for persistent knee pain and crepitus. Therefore caution must be exercised when interpreting results obtained using this feature. Third, there is no universally applicable reference standard for knee OA, so the recommendations were mainly based on radiographic evidence when clinical features were examined, or on clinical, MRI or arthroscopic evidence when radiographic features were examined. Whether this is an appropriate approach is open to debate. Finally, all propositions relate to people over age 40, which is the target age for common OA. Whether recommendations would differ for less typical patients under this age was not examined.

In conclusion, 10 key recommendations for the diagnosis of knee OA have been produced based on expert consensus and a systematic literature review. A confident diagnosis may be made according to three symptoms (knee pain, short-lived morning stiffness and functional limitation) and determination of three signs on examination (crepitus, restricted movement and bony enlargement) without a requirement for imaging. This may be especially useful for primary care. Nevertheless, plain radiography and occasionally other investigations may be considered for the diagnosis of atypical cases when additional pathology is suspected. These recommendations were examined in two test populations and the level of evidence and summary strength of recommendations were provided to guide their use.
Recommendations

Background risk

Risk factors
- Age
- Gender
- BMI
- Occupation
- Family history of OA
- History of knee injury

Symptoms
- Knee pain
- Brief morning stiffness
- Functional limitation

Signs
- Crepitus
- Restricted movement
- Bony enlargement

Radiographic changes
- Osteophyte
- Narrowing
- Subchondral sclerosis
- Subchondral cysts

OA

Figure 4 Major components in the diagnosis of knee osteoarthritis (OA). BMI, body mass index.

Mild Moderate Severe

Author affiliations
1. Departamento de Reumatologia del Asturias, Oviedo, Spain
2. Department of Rheumatology and Clinical Immunology, University Medical Centre, Utrecht, The Netherlands
3. Department of General Practice, Erasmus MC University Medical Centre, Rotterdam, The Netherlands
4. MRC Environmental Epidemiology Resource Centre, Southampton General Hospital, Southampton; Musculoskeletal Biochemical Research Unit, University of Oxford, UK
5. Department of Rheumatology, St Vincent’s University Hospital, Dublin, Ireland
6. Service de RMR, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
7. University of Nottingham, Nottingham, UK
8. 2nd Department of Medicine, Centre for Rheumatology Lower Austria, Stockerau, The Netherlands
9. Department of Orthopaedics, Clinical Sciences Lund, Lund University, Lund, Sweden
10. Department of Rheumatology, Larrey University Hospital, Toulouse, France
11. Institute of Rheumatology, Na Slupi 4, Prague, Czech Republic
12. University of Padova, Italy
13. Department of Rheumatology, Laryear University Hospital, Toulouse, France
14. Department of Rheumatology, University Medical Centre, Keel, UK
15. Department of Rheumatology, St Vincent’s University Hospital, Dublin, Ireland
16. Department of PMR, Rheumatology Division, Akdeniz University, Antalya, Turkey
17. Department of Rheumatology, Larrey University Hospital, Toulouse, France
18. 2nd Department of Medicine, Centre for Rheumatology Lower Austria, Stockerau, The Netherlands
19. University of Padova, Italy
20. Department of Rheumatology, Larrey University Hospital, Toulouse, France

Acknowledgements
We thank the European League Against Rheumatism for financial support, Helen Richardson for co-ordination and Joanna Rambowski for assistance with the literature search and paper collection.

Funding
Financial support was received from the European League Against Rheumatism.

Competing interests
None.

Provenance and peer review
Not commissioned; externally peer reviewed.

REFERENCES


EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis

W Zhang, M Doherty, G Peat, et al.

Ann Rheum Dis 2010 69: 483-489 originally published online September 17, 2009
doi: 10.1136/ard.2009.113100

Updated information and services can be found at:
http://ard.bmj.com/content/69/3/483.full.html

These include:

Data Supplement
"Web Only Data"
http://ard.bmj.com/content/suppl/2010/04/16/ard.2009.113100.DC1.html

References
This article cites 50 articles, 25 of which can be accessed free at:
http://ard.bmj.com/content/69/3/483.full.html#ref-list-1

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/